Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics
GET POWR RATINGS... FREE!
MIRM Stock Price Chart Interactive Chart >
MIRM Price/Volume Stats
|Current price||$18.30||52-week high||$26.31|
|Prev. close||$18.49||52-week low||$13.85|
|Day high||$19.37||Avg. volume||113,539|
|50-day MA||$16.10||Dividend yield||N/A|
|200-day MA||$17.87||Market Cap||558.44M|
Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
Most Popular Stories View All
MIRM Latest News Stream
|Loading, please wait...|
MIRM Latest Social Stream
View Full MIRM Social Stream
Latest MIRM News From Around the Web
Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for the development, including conducting clinical stud
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
FOSTER CITY, Calif. & OSAKA, Japan, September 21, 2021--Mirum and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
FOSTER CITY, Calif., September 13, 2021--Mirum Submits European MAA for Maralixibat in ALGS Supported by New Positive Results from Natural History Study Comparison
FOSTER CITY, Calif., September 10, 2021--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM Price Returns